Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

V. Joly, M. Moroni, E. Concia, A. Lazzarin, B. Hirschel, J. Jost, F. Chiodo, Z. Bentwich, W. C. Love, D. A. Hawkins, E. G.L. Wilkins, A. J. Gatell, N. Vetter, C. Greenwald, W. W. Freimuth, W. De Cian, D. Cooper, J. Hoy, D. Shaw, A. StreetE. Tschachler, N. Vetter, N. Clumeck, J. Demonty, B. Vandercam, L. Mathiesen, G. Sheehan, E. Auvergnat, G. Bouvet, G. Delzant, V. Joly, J. Kisterman, Lafeuillade, J. Lang, G. Lepeu, P. Massip, F. Raffi, K. Arasteh, H. Busch, M. Hartman, H. Jablonowski, H. Jaeger, A. Mutz, H. Rasokat, J. Rockstroh, B. Ruf, I. Schedel, W. Stille, D. Banhegyi, Z. Bentwitch, I. Yust, F. Chiada, E. Concia, A. Lazzarin, M. Moroni, M. Piazza, M. Soranzo, J. Borleffs, G. Schrey, C. Tannapel, A. Horban, A. Sonnerborg, B. Clotet, A. Gatell, J. Lahoz, M. Leal, B. Hirschel, J. Jost, I. Ahmed-Jushuf, C. Bradbeer, R. Brettle, D. Hawkins, W. Love, A. Pozniak, K. Radcliffe, S. Tchamouroff, E. Wilkins

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)


We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Original languageEnglish
Pages (from-to)3155-3157
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Issue number11
Publication statusPublished - 9 Nov 2000

Cite this